Speech-derived Digital Biomarkers Study
Launched by HACKENSACK MERIDIAN HEALTH · May 20, 2025
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
The Speech-derived Digital Biomarkers Study is looking at a new application that analyzes voice characteristics to help diagnose mild cognitive impairment (MCI) and Alzheimer's disease (AD). The main goal is to see if this app can accurately identify these conditions as well as a doctor can. This study is currently recruiting participants who are 50 years old or older and have been diagnosed with MCI or Alzheimer's by a physician. Participants should also be able to speak and read English fluently and have no medical conditions that might affect their voice.
If you or a loved one is interested in participating, you'll need to be able to commit to all parts of the study and provide informed consent. This means you understand what the study involves and agree to take part. However, individuals under 50, those with certain medical conditions like Parkinson's or cancer, or anyone with speech issues that might interfere with voice recording won't be eligible. If you participate, you can expect to contribute to important research that could improve how these conditions are diagnosed in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Males and females between the ages of 50 and above
- • Willing and capable of participating in all aspects of the study
- • Willing and capable of giving informed consent
- • Diagnosis of MCI or Alzheimer's by the physician
- • Subjects are free of any medical condition(s) that, according to exclusion criteria, might audibly affect voice characteristics
- • Subject must be able to speak and read with fluency in the English language.
- Exclusion Criteria:
- • All participants below 50 years
- • Failure to provide informed consent
- * Individuals with the following medical conditions will be excluded:
- • i) Parkinson's disease ii) Huntington's disease iii) Cancer and active cancer treatments
- • Persons with speech characteristics (heavy accents, slurring, stuttering, etc.) that would interfere with voice recording or voice analysis
About Hackensack Meridian Health
Hackensack Meridian Health is a leading healthcare organization based in New Jersey, dedicated to advancing medical research and improving patient care through innovative clinical trials. As a prominent sponsor of clinical research, Hackensack Meridian Health is committed to fostering collaboration between researchers, healthcare professionals, and patients to develop and evaluate cutting-edge therapies and interventions. With a focus on enhancing health outcomes and addressing pressing medical needs, the organization leverages its extensive network of hospitals, specialty care centers, and research facilities to advance clinical knowledge and contribute to the global body of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hackensack, New Jersey, United States
Patients applied
Trial Officials
Sakshi Jain, MD
Principal Investigator
Hackensack Meridian Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported